Although further study is required to identify the involvement of the HIF-Epo pathway in RCC pathogenesis, the pathway may be a new molecular therapeutic target candidate for the treatment of RCC, particularly in advanced stages. Here, EPO is linked to renal cell adenocarcinoma.